Key figures Q2 2021

KDKK	01/07/21 30/09/21	01/07/20 30/09/20	01/01/21 30/09/21	01/01/20 30/09/20
Net sales	0	0	0	0
Operating profit (EBIT)	-3,429	-1,650	-9,791	-3,149
Result per share (DKK)	-0.12	-0.07	-0.35	-0.54
Equity ratio	0.79	0.78	0.79	-0.78

Number of shares on the 01/01/20: 1
Number of shares on the 08/04/20: 175,760
Number of shares on the 26/06/20: 14,060,800
Number of shares on the 02/10/20: 20,730,800
Number of shares on the 30/09/21: 22,433,139

CEO of DanCann Pharma, Jeppe Krog Rasmussen, comments:

A busy third quarter of 2021 has come to an end. During the period we spent a significant number of resources on finalizing the acquisition of CannGros, which was official on 5th October. The commercial activities related to the acquisition mean, that we now have a portfolio of products generating income for the first time in DanCann Pharma’s history - and our Q4/year-end report will be a long-awaited testament to this.

The fact that Aurora Nordic has withdrawn their product (Sedamen, as of 15th November 2021) from the Danish market means that we – with our three CannGros products - have a market share of 100 per cent in relation to the Danish Pilot Programme for Medical Cannabis. However, we do share a genuine and heart-felt compassion with the many patients, who no longer can be treated with Sedamen, and we aim to fill this gap with complementary products as soon as we possibly can. We do have an overall purpose of serving the best interest of the patients.

With the acquisition of CannGros we also bought the pipeline of a pending application at the Danish Medical Agency for an oil product containing extracts of cannabis. We expect the Danish Medicines Agency's (“DMA”) next feedback round on the product application before the end of 2021 and expect to have the approval with an expected market launch in the first half of 2022. Furthermore, we are finalizing the details in our EU-GMP application for Biotech Pharm1 and expect to send in our application during end-2021/start 2022, with an expected approval from the DMA in the first half of 2022.

As a company we are facing a major milestone when we will be ready with our first biomaterial. A biomaterial produced under indoor conditions in closed hermetic chambers, produced under best practice GACP- and EU-GMP conditions, with the result of an output of approx. 2,500 kilograms. dried flower/granular (biomaterial) per year.

We expect to be able to deliver our first bulk biomaterials for further processing by mid-2022. Our ultimate mission is always to ensure that patients have access to various quality-assured treatments with cannabinoid substances – this by delivering a standardized product, repeatedly, every single time, without any supply issues (= quality). We, as a company, are set in the world and in the market to make a difference, a difference for the many who need a company just like us.

Highlights during the period

THU, JUL 08, 2021

The Board of Directors of DanCann Pharma A/S convenes an Extraordinary General Meeting and proposes that the Meeting resolves a directed share issue. The Board of Directors of DanCann Pharma A/S (publ) (“DanCann Pharma” or “the Company”) has today decided to convene an Extraordinary General Meeting of the Company on 23 July 2021 and proposes that the Board of Directors have the mandate to resolve a directed issue

TUE, JUL 13, 2021

DanCann Pharma A/S: Tetra Bio-Pharma Accelerates REBORN1© Trial. DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that the Central Ethics Committee has approved the proposed protocol modfications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study.

MON, JUL 26, 2021

DanCann Pharma A/S has carried out a directed issue of shares of approx. DKK 6.375 million and warrants, in combination with obtaining a loan facility of SEK 13.7 million. DanCann Pharma A/S (Publ) (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announces that based on the resolutions to issue shares and warrants on the Extraordinary General Meeting on 23 July 2021, the Company has issued a total of 1,702,339 new shares at price of DKK 3.745 per share (which corresponds to the closing price as of 22 July 2021), where the Board of Directors and Executive Management participate, which adds the Company a total of DKK 6,375,259 and a total of 1,702,339 new warrants, this in combination with obtaining a loan facility of SEK 13,700,000, which secure DanCann Pharma financing a total of approx. DKK 16.326 million (based on current currency exchange rate).

TUE, JUL 27, 2021

DanCann Pharma A/S’ CEO and CCO have subscribed for shares and warrants in the directed issue. DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announces that Jeppe Krog Rasmussen, Founder, Board Member and CEO at DanCann Pharma A/S has privately through his holding company (Xignotus Capital ApS) subscribed for 267,023 new shares, equivalent to a subscription amount of DKK 1,000,001 and 267,023 warrants in DanCann Pharma A/S and John Morell Frellsen has privately through his holding company (Morellco Holding ApS) subscribed for 25,000 new shares, equivalent to a subscription amount of DKK 93,625, as well as 25,000 warrants.

THU, AUG 12, 2021

DanCann Pharma A/S has reached a historic milestone with the first ever cannabis batch in Biotech Pharm1. DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announce, that the ambitious pharma company has just completed its first successful production run of biomaterial a few weeks after the Company carried out a directed issue of shares and at the same time received loan capital of a double-digit DKK million amount.

FRI, SEP 03, 2021

DanCann Pharma A/S: Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™. DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that Tetra has received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com